Outcomes after allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia patients with der(1;7)(q10;p10)
oleh: Hiroki Mizumaki, Ken Ishiyama, Jun Aoki, Jinichi Mori, Shohei Mizuno, Noriko Doki, Takahiro Fukuda, Naoyuki Uchida, Masahito Onizuka, Masatsugu Tanaka, Yuta Katayama, Yukiyasu Ozawa, Kazuhiro Ikegame, Satoru Takada, Toshiro Kawakita, Nobuyuki Aotsuka, Yoshiko Atsuta, Masamitsu Yanada
| Format: | Article |
|---|---|
| Diterbitkan: | Wiley 2023-02-01 |
Deskripsi
Abstract The prognosis of acute myeloid leukemia (AML) patients with der(1;7)(q10;p10) who underwent allogeneic hematopoietic stem cell transplantation (allo‐SCT) is unclear due to its rarity. We retrospectively analyzed 151 AML patients with der(1;7)(q10;p10) and compared the findings with those of 853 AML patients with monosomy 7 or chromosome 7q deletion (‐7/del(7q)) using Japanese nationwide registry data. The der(1;7)(q10;p10) group showed significantly better transplant outcomes than the ‐7/del(7q) group. In the multivariate analysis of the der(1;7)(q10;p10) group, additional chromosomal abnormalities and a poor performance status significantly influenced the survival. In conclusion, allo‐SCT is a feasible treatment option for AML patients with der(1;7)(q10;p10).